Authors
Latest:
Distinguishing Between the Different Subtypes of SarcomasKiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, speaks on distinguishing between the different subtypes of sarcomas.
Latest:
HR+/HER2- Metastatic Breast Cancer: Future Directions in CareClosing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.
Latest:
Molecular Targets in Inflammatory Breast CancerKomal L. Jhaveri, MD, Assistant Professor, Department of Medicine, NYU Langone Medical Center, discusses molecular targets in inflammatory breast cancer.
Latest:
Expert Highlights Areas of Research in MCLKrish Patel, MD, discusses the areas of research he finds particularly interesting for the treatment of patients with mantle cell lymphoma.
Latest:
Novel Treatment Strategies in Endometrial CancerClosing out their program on endometrial carcinoma management, key opinion leaders highlight key novel therapeutic strategies in the evolving treatment landscape.
Latest:
The Impact of CTCs on Survival in Cervical CancerKrishnansu S. Tewari, MD, FACOG, FACS, discusses a trial looking at the impact of CTCs on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer.
Latest:
The Results From a Phase II Study Analyzing First-Line Eribulin MesylateKristi McIntyre, MD, a physician with Texas Oncology, discusses the results of a phase II, multicenter, single-arm study looking at eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.
Latest:
Lenalidomide Break Possible? Study Shows Hope for MRD-Negative MyelomaA new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.
Latest:
Findings With the Antibody Drug Conjugate D3-GPC2-PBDKristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses findings with the antibody-drug conjugate (ADC) D3-GPC2-PBD for neuroblastoma presented at the 2018 AACR Annual Meeting.
Latest:
Validated Biomarkers in Renal Cell Carcinoma: The Search ContinuesSeveral immunotherapies are now approved for the management of metastatic RCC. However, immunotherapy-based combination regimens are associated with high rates of treatment-related toxicities and do not yield objective responses in a significant proportion of patients.
Latest:
Radiosurgery Versus Radiotherapy Followed by Whole Brain Radiation for Brain MetastasesKurt Jaeckle, MD, professor of neurology and oncology, Mayo Clinic, discusses radiosurgery versus radiotherapy followed by whole brain radiation for brain metastases.
Latest:
Bundled Payment: Practice Savior or Killer?Although there is still disagreement about what it means, the bundling of payments revolves around oncologists being paid a set fee for managing their patients’ care.
Latest:
Bladder Cancer Outcomes in Men vs. WomenKyle A. Richards, MD, assistant professor, University of Wisconsin, discusses bladder cancer outcomes in men vs. women.
Latest:
Background for Neoadjuvant Immunotherapy Improving TNBC PrognosisLajos Pusztai, MD, DPhil, discusses the promise of neoadjuvant immunotherapy trials including the KEYNOTE-522 trial evaluating pembrolizumab plus chemotherapy in patients with triple-negative breast cancer.
Latest:
Methods and Study Design of KEYNOTE-522 for TNBCLajos Pusztai, MD, DPhil, discusses the methods and design of the phase 3 KEYNOTE-522 trial.
Latest:
Targeted Treatments Emerge for HER2 Mutations in Lung CancerHER2 mutations have been identified as another oncogenic driver in the growing list of actionable targets in non–small cell lung cancer. Based on a mounting body of evidence on the impact of HER2 mutations in lung cancer and the growing focus on personalized medicine, the HER2 receptor has gained focus as a potential target for precision medicine treatments for patients with NSCLC.
Latest:
The Role of Lenvatinib in NSCLC TreatmentLars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses the role of lenvatinib in treating patients with non-small cell lung cancer (NSCLC).
Latest:
Stereotactic Body Radiotherapy Can Benefit Some Patients with HCCLaura A. Dawson, MD, FRCPC, discusses key takeaways from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib vs sorafenib alone in patients with hepatocellular carcinoma.
Latest:
An Overview of the I-SPY 2 TrialLaura J. Esserman, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.
Latest:
Reardon on ReACT: First Immunotherapy to Show Benefit in GlioblastomaTargeted Oncology spoke with David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president of the Society for Neuro-Oncology, and lead author on the ReACT trial to better understand the significance of the study results for patients with glioblastoma.
Latest:
Evaluating the Next Steps for Research in MyelofibrosisLaura Michaelis, MD, discusses the next steps for research in the treatment of myelofibrosis following the addition of fedratinib to the armamentarium of JAK inhibitors.
Latest:
Expert Discusses Quizartinib Promise in AMLThe investigational tyrosine kinase inhibitor quizartinib is extremely promising as a monotherapy for patients with <em>FLT3-ITD–</em>positive relapsed acute myeloid leukemia.
Latest:
Rationale for Evaluating Ceritinib in ALK-Positive Patients With NSCLCLaura Quan Man Chow, MD, FRCPC, discusses the rationale for evaluating ceritinib in patients with <em>ALK</em>-positive non–small cell lung cancer in the ASCEND-7 trial.
Latest:
Longer Letrozole Treatment Shows Limited Benefit in Early Breast CancerExtending treatment with letrozole by an additional 5 years after 5 years of successful treatment did not improve disease-free survival or overall survival in postmenopausal women with early-stage hormone receptor -positive breast cancer.
